Liver Cancer/HCC
Liver Cancer/HCC
ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 02 June 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.
Coverage of the 2014 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 02 December 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
12/2/14
HCV Genotype 3, Hispanic Ethnicity Linked to Higher Risk of Cirrhosis, Liver Cancer
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 08 October 2014 00:00
- Written by Liz Highleyman
People with hepatitis C virus (HCV) genotype 3 are more likely to progress to liver cirrhosis and hepatocellular carcinoma (HCC) compared to people with other genotypes, according to a recent report. A related study found that people of Hispanic/Latino ethnicity are also more likely to develop advanced liver disease.
Coverage of the 2014 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 02 December 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
12/2/14
Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 03 July 2014 00:00
- Written by JAMA
The mTOR inhibitor everolimus (Afinator) failed to increase overall survival for people with advanced hepatocellular carccinoma (HCC) who were previously unsuccessfully treated with sorafenib, according to results from the EVOLVE-1 trial published in the July 2 edition of JAMA.
More Articles...
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- AASLD 2013: Liver Meeting Ends with Hepatitis C Debrief and the Future of Treatment
- AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated
- Coverage of the 2013 AASLD Liver Meeting
Web Design and Development by